Nanotechnology Stocks To Research – February 13th

OSI Systems, Biodexa Pharmaceuticals, NVE, Virpax Pharmaceuticals, and Clene are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks refer to stocks of companies involved in the research, development, or commercialization of products and technologies based on nanotechnology, which involves manipulating materials at the atomic and molecular scale. These stocks may encompass a wide range of industries, including healthcare, electronics, energy, and materials science, and can be affected by market trends, regulatory developments, and scientific breakthroughs in the field of nanotechnology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ OSIS traded up $0.65 during trading hours on Thursday, hitting $209.56. 36,421 shares of the company’s stock were exchanged, compared to its average volume of 215,765. OSI Systems has a 1-year low of $126.57 and a 1-year high of $212.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 1.74 and a beta of 1.19. The company’s 50-day moving average price is $180.23 and its 200-day moving average price is $159.03.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Biodexa Pharmaceuticals stock traded up $0.19 during trading hours on Thursday, hitting $4.99. The stock had a trading volume of 147,764 shares, compared to its average volume of 843,490. The company’s 50-day simple moving average is $4.35. Biodexa Pharmaceuticals has a fifty-two week low of $3.50 and a fifty-two week high of $74.00.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded up $0.49 during trading hours on Thursday, hitting $72.34. The stock had a trading volume of 5,288 shares, compared to its average volume of 27,032. The company has a 50-day moving average of $77.60 and a two-hundred day moving average of $78.55. The company has a market cap of $350.13 million, a PE ratio of 23.47 and a beta of 1.11. NVE has a fifty-two week low of $67.35 and a fifty-two week high of $90.24.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Virpax Pharmaceuticals stock traded up $0.01 during trading hours on Thursday, hitting $0.28. The stock had a trading volume of 468,544 shares, compared to its average volume of 444,378. The company has a 50-day moving average of $0.33 and a two-hundred day moving average of $0.60. Virpax Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $5.48.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Clene stock traded up $0.02 during trading hours on Thursday, hitting $4.62. The stock had a trading volume of 16,795 shares, compared to its average volume of 60,384. The company has a 50-day moving average of $4.82 and a two-hundred day moving average of $5.05. The company has a market cap of $38.48 million, a PE ratio of -0.88 and a beta of 0.24. Clene has a fifty-two week low of $3.82 and a fifty-two week high of $10.65.